Key takeaways
Rinvoq (upadacitinib) and Dupixent (dupilumab) are both medications used to treat inflammatory conditions, such as eczema. However, they belong to different medication classes and have distinct characteristics. Rinvoq is a Janus kinase (JAK) inhibitor taken orally, while Dupixent is a monoclonal antibody given as a subcutaneous (under the skin) injection. Rinvoq is used for a variety of conditions, including rheumatoid arthritis and ulcerative colitis, and is typically taken once daily. In contrast, Dupixent is used for conditions like asthma and eosinophilic esophagitis, with dosing usually every 2 weeks or monthly. Rinvoq is available in both tablet and liquid forms, whereas Dupixent comes as a pre-filled pen or syringe. Common side effects of Rinvoq include a higher risk of infections and acne, while Dupixent may cause injection site reactions and eye inflammation. Additionally, Rinvoq can interact with many medications and should not be taken with grapefruit. Neither medication is available in a generic form.
